% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Lang:283176,
author = {T. J. L. Lang and F. Damm$^*$ and L. Bullinger$^*$ and M.
Frick$^*$},
title = {{M}echanisms of {R}esistance to {S}mall {M}olecules in
{A}cute {M}yeloid {L}eukemia.},
journal = {Cancers},
volume = {15},
number = {18},
issn = {2072-6694},
address = {Basel},
publisher = {MDPI},
reportid = {DKFZ-2023-01955},
pages = {4573},
year = {2023},
abstract = {In recent years, great progress has been made in the
therapy of AML by targeting cellular processes associated
with specific molecular features of the disease. Various
small molecules inhibiting FLT3, IDH1/IDH2, and BCL2 have
already gained approval from the respective authorities and
are essential parts of personalized therapeutic regimens in
modern therapy of AML. Unfortunately, primary and secondary
resistance to these inhibitors is a frequent problem. Here,
we comprehensively review the current state of knowledge
regarding molecular processes involved in primary and
secondary resistance to these agents, covering both genetic
and nongenetic mechanisms. In addition, we introduce
concepts and strategies for how these resistance mechanisms
might be overcome.},
subtyp = {Review Article},
keywords = {AML (Other) / BCL2 (Other) / FLT3 (Other) / IDH1/IDH2
(Other) / gene mutations (Other) / precision medicine
(Other) / resistance (Other) / small molecule (Other) /
targeted therapy (Other) / venetoclax (Other)},
cin = {BE01},
ddc = {610},
cid = {I:(DE-He78)BE01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37760544},
doi = {10.3390/cancers15184573},
url = {https://inrepo02.dkfz.de/record/283176},
}